Your browser doesn't support javascript.
loading
The global threat of antimicrobial resistance: science for intervention.
Roca, I; Akova, M; Baquero, F; Carlet, J; Cavaleri, M; Coenen, S; Cohen, J; Findlay, D; Gyssens, I; Heuer, O E; Kahlmeter, G; Kruse, H; Laxminarayan, R; Liébana, E; López-Cerero, L; MacGowan, A; Martins, M; Rodríguez-Baño, J; Rolain, J-M; Segovia, C; Sigauque, B; Tacconelli, E; Wellington, E; Vila, J.
Afiliação
  • Roca I; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Akova M; Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey ; ESCMID Executive Committee, Basel, Switzerland.
  • Baquero F; Department of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain.
  • Carlet J; Fondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France.
  • Cavaleri M; European Medicines Agency (EMA), London, UK.
  • Coenen S; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Cohen J; Brighton and Sussex Medical School, Brighton, UK.
  • Findlay D; Global Commercial Lead, GlaxoSmithKline (GSK), London, UK.
  • Gyssens I; Department of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Heuer OE; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Kahlmeter G; Clinical Microbiology, Central Hospital, Växjö, Sweden ; ESCMID Executive Committee, Basel, Switzerland ; EUCAST Steering Committee, Växjö, Sweden.
  • Kruse H; WHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark.
  • Laxminarayan R; Center for Disease Dynamics, Economics and Policy, Washington, DC, USA ; Princeton University, Princeton, NJ, USA.
  • Liébana E; Scientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy.
  • López-Cerero L; Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.
  • MacGowan A; Department of Medical Microbiology, Southmead Hospital, Bristol, UK ; EUCAST Steering Committee, Växjö, Sweden.
  • Martins M; School of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland.
  • Rodríguez-Baño J; Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain ; ESCMID Executive Committee, Basel, Switzerland.
  • Rolain JM; Aix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France.
  • Segovia C; Instituto de Salud Carlos III, ISCIII, Madrid, Spain.
  • Sigauque B; Centro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique.
  • Tacconelli E; Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany ; ESCMID Executive Committee, Basel, Switzerland.
  • Wellington E; School of Life Sciences, University of Warwick, Coventry, UK.
  • Vila J; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain ; ESCMID Executive Committee, Basel, Switzerland.
New Microbes New Infect ; 6: 22-9, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26029375
ABSTRACT
In the last decade we have witnessed a dramatic increase in the proportion and absolute number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant bacteria are currently considered as an emergent global disease and a major public health problem. The B-Debate meeting brought together renowned experts representing the main stakeholders (i.e. policy makers, public health authorities, regulatory agencies, pharmaceutical companies and the scientific community at large) to review the global threat of antibiotic resistance and come up with a coordinated set of strategies to fight antimicrobial resistance in a multifaceted approach. We summarize the views of the B-Debate participants regarding the current situation of antimicrobial resistance in animals and the food chain, within the community and the healthcare setting as well as the role of the environment and the development of novel diagnostic and therapeutic strategies, providing expert recommendations to tackle the global threat of antimicrobial resistance.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2015 Tipo de documento: Article